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1

Abstract.

2

methicillin-resistant S. aureus (MRSA) infections and recently with heteroresistant vancomycin

3

intermediate S. aureus (hVISA) and vancomycin intermediate S. aureus (VISA) infections. While

4

vancomycin is traditionally a first line and relatively effective antibiotic, its continued use is under

5

question, as reports of heteroresistance in S. aureus isolates are increasing. Both hVISA and VISA

6

infections are associated with complicated clinical courses and treatment failures. The prevalence,

7

mechanism of resistance, clinical significance, and laboratory detection of hVISA and VISA

8

infections are not conclusive, making it difficult to apply research findings to clinical situations.

9

We provide an evidence based review of S. aureus isolates expressing heterogenic and reduced

10

Staphylococcus aureus has proven to be a major pathogen with the emergence of

susceptibility to vancomycin.

3
11

Introduction

12

Methicillin-resistant Staphylococcus aureus (MRSA) is the most commonly encountered bacteria

13

in hospitals and community settings1 and is associated with invasive infections ranging in severity

14

from mild to fatal.2 Vancomycin is considered the standard treatment for empiric and definitive

15

serious MRSA infections.2

16

susceptibility to vancomycin have emerged. The formation of intermediate resistant isolates is

17

likely caused by selection pressure from ever-present and longstanding use of vancomycin.3-5 Poor

18

patient outcomes are attributed to heteroresistant vancomycin intermediate S. aureus (hVISA) and

19

vancomycin intermediate S. aureus (VISA) infections.6-8 Herein we review the prevalence,

20

laboratory detection and interpretation, resistance mechanisms, risk factors and outcomes,

21

treatment options, and infection control strategies for hVISA and VISA.

22

publications were identified using PubMed, Embase, and Cochrane Central Register of Controlled

23

Trials.

In recent years, infections caused by MRSA with reduced

Peer-reviewed

24
25

Prevalence of hVISA and VISA

26

The first clinical strain of S. aureus with intermediate resistance to vancomycin, designated Mu50,

27

was reported in 1997 from Japan.9,10 The first hVISA isolate, designated Mu3, was identified in

28

Japan one year earlier from a patient with MRSA pneumonia unresponsive to vancomycin.9 Since

29

then, hVISA and VISA cases have been reported in the United States, United Kingdom, China,

30

Australia, Turkey, France, Belgium, Germany, Italy, Brazil, and South Korea.11

31

prevalence of hVISA is unknown, and estimates vary widely because of non-standardized

32

detection methodologies or absence of routine hVISA screening, variation in interpretation,

The true

4
33

geographical location, clinical setting, and differing patient populations.12-19 Reported rates of

34

hVISA throughout the world range from 0 to 73.7%.18

35
36

One retrospective study evaluated MRSA strains with heterogenic intermediate resistance to

37

vancomycin over a 22-year period in three Detroit hospitals. The prevalence of these organisms

38

increased from 2.2% (1986 – 1993) and 7.6% (1992 – 2002) to 8.3% between 2003 and 2007.16

39

Only 14 of the 1,498 (0.93%) MRSA isolates were identified as VISA. There was no apparent

40

pattern of increasing prevalence over the three time periods for VISA isolates. An increase in

41

hVISA was also described in a similar retrospective study from Turkey of 1.6% in 1998 to 36%

42

in 2001.20 Because clonality was not evaluated in either study, the increase in prevalence may

43

have reflected clonal spread rather than true prevalence.

44

underestimated because the isolates were stored for prolonged periods in glycopeptide-free media,

45

which may result in a loss of resistance.21 Two surveillance studies conducted in 2009 and 2011

46

in over 40 U.S. medical centers determined rates of antimicrobial resistance among S. aureus

47

isolates collected from patients with infections.22,23 The rates of hVISA among MRSA isolates in

48

2011 were higher than in 2009 (1.2% vs. 0.4%, P = 0.003).22 Of note, strains of VISA were not

49

detected.22,23 While the current prevalence of VISA is low, these organisms may become more

50

common in the future. Data suggests that heteroresistance is a precursor to VISA, therefore the

51

suspected increase in prevalence of hVISA may predict more VISA infections. Increased use of

52

vancomycin provides selection pressure for further emergence of VISA. Based on available data,

53

hVISA appears to be on the rise, yet VISA still remains a rare occurrence. Additional studies are

54

needed to determine appropriate surveillance methods because retrospective studies are

Prevalence may have been

5
55

complicated by the ability of hVISA to revert back to vancomycin-susceptible S. aureus (VSSA)

56

and VISA to revert back to hVISA.

57
58

hVISA and VISA Laboratory Detection and Interpretation

59

Further discussion of hVISA and VISA require that clinical and microbiologic definitions are

60

addressed. In 2006, the Clinical and Laboratory Standards Institute (CLSI) lowered vancomycin

61

minimum inhibitory concentration (MIC) breakpoints for S. aureus.24 The CLSI breakpoints by

62

broth microdilution (BMD) currently define vancomycin susceptibility as an MIC  2 μg/mL,

63

vancomycin-intermediate susceptibility as an MIC of 4 to 8 μg/mL, and vancomycin resistance as

64

an MIC of 16 μg/mL (Table 1).25 Vancomycin MIC breakpoints were lowered in an effort to

65

increase detection of potentially heterogeneous-intermediate isolates because of reported

66

associations between vancomycin treatment failure and S. aureus isolates with MICs ≥ 4

67

µg/mL.7,8,25 Heteroresistance refers to the presence of less susceptible subsets within a larger

68

population of fully antimicrobial-susceptible microorganisms.5

69

methods, hVISA isolates are susceptible to vancomycin (MIC 2 μg/mL) but contain

70

subpopulations that express reduced vancomycin susceptibility (MIC  4 μg/mL).11

When tested using routine

71
72

Detection of hVISA is a great challenge in clinical microbiology laboratories because reliable and

73

practical methods are not currently available for routine use.

74

present in low frequencies (1 x 106) and can grow in higher vancomycin concentrations than the

75

MIC predicts. Such small populations may not be detected by the inocula (5 x 105 CFU/mL)

76

used in standard CLSI microbiology methods. As a result, hVISA isolates are likely undetected

77

in clinical laboratories that use traditional MIC testing methodology.13 Population analysis

Heteroresistant subpopulations are

6
78

profiling with area under the curve (PAP-AUC) is the current reference standard method for

79

confirming hVISA and is the most reliable and reproducible test. However PAP-AUC is labor-

80

intensive, time consuming (3 to 5 days), and costly for use in clinical microbiology

81

laboratories.17,19,26

82

glycopeptide resistance detection (GRD), marcromethod E-test (MET) and brain heart infusion

83

(BHI) screen agar plates (Table 2).27-29 However, none of these tests have the same degree of

84

sensitivity and specificity as the PAP-AUC test, with issues of reproducibility and variability, in

85

reporting results.19 Until a suitable hVISA detection method becomes available for use in clinical

86

microbiology laboratories, routine testing is not currently recommended.2 Currently, clinical

87

screening for hVISA isolates in high-risk patients is favored (Table 3), particularly in patients who

88

do not respond to vancomycin. Further research is warranted to develop a detection method that

89

is practical, cost-effective, and reliable for routine use in clinical settings.

Consequently, several screening methods have been developed, such as

90
91

Non-automated MIC methods for the detection of VISA are recommended by the Centers for

92

Disease Prevention and Control (CDC).30 Acceptable non-automated MIC methods for detecting

93

VISA include BMD per CLSI, agar dilution, and Etest (0.5 McFarland).

94

methods and vancomycin screen agar plates can be useful in the detection of VISA isolates with a

95

vancomycin MIC of 8 μg/mL, sensitivity levels have not been determined for S. aureus with

96

vancomycin MICs of 4 μg/mL.30 In these situations, a second method, such as BMD per CLSI

97

criteria, should be used to confirm VISA isolates.30

30

Though automated

98
99

Current susceptibility testing methods do not consistently distinguish between MICs of 1 and 2

100

μg/mL.2,31 Therefore, laboratory results should indicate the methodology used, because

7
101

vancomycin MIC results will differ between methods and may alter treatment decisions. 11 In

102

comparison to the CLSI BMD method, automated detection methods, particularly Phoenix system

103

and Vitek, tend to underestimate the MIC, while E-test and MicroScan (prompt method) may

104

overestimate the MIC.31 Precision of these methods is clinically important as higher vancomycin

105

MICs (> 1.5 μg/mL) are associated with poorer outcomes (e.g., increased mortality, recurrence,

106

delayed response, treatment failure, prolonged hospitalization), particularly in high inoculum

107

infections and with a higher proportion of hVISA presence.25,32 Alternative therapies should be

108

considered for patients receiving vancomycin therapy who are persistently bacteremic (≥ 7 days)

109

or who have no clinical improvement despite source control with an MIC of  1.5 μg/mL by

110

Etest.2,31,32

111
112

Resistance Mechanisms of hVISA and VISA

113

Evidence suggests that hVISA and VISA arise during continued or sub-optimal exposure to

114

vancomycin.7,33 The proposed mechanism is selective pressure by vancomycin resulting in the

115

development of rare vancomycin-resistant clones that progress to hVISA and, with continued-

116

exposure, to a uniform population of VISA clones.5,9 These isolates have significant differences

117

in cell physiology, including morphologic changes and genetic alterations. Strains of hVISA and

118

VISA are characterized by thicker cell walls that correlate with increased vancomycin MICs. 34

119

Cell wall thickening impairs intracellular penetration of vancomycin rendering it ineffective.5,34

120

In addition, hVISA and VISA are associated with slower growth rates than fully susceptible

121

strains, which may contribute to persistent and recurrent infections.35 Other mechanisms of

122

resistance include alterations in transcriptional and metabolic genes and loss-of-function mutations

123

that disturb critical cell wall biosynthesis.11 The accessory gene regulator (agr) operon directs

8
124

many critical virulence pathways, particularly the production of exotoxins.11 In hVISA and VISA

125

strains, agr function is reduced, favoring the development of vancomycin resistance and

126

potentially promoting biofilm production that ultimately enhances the survival of hVISA and

127

VISA.33,36,37

128
129

Risk Factors and Outcomes Associated with hVISA and VISA

130

Heteroresistance has been reported in MRSA isolates with MICs as low as 0.5 µg/mL and in cases

131

where vancomycin was minimally effective.6,16

132

vancomycin treatment failures and mortality with vancomycin susceptible MRSA strains,

133

particularly those with MICs of 1.5 or 2 µg/mL.25,32,38-40

134

evaluated high versus low vancomycin MICs (≥ 1.5 µg/mL vs < 1.5 µg/mL, respectively) on

135

clinical outcomes in adults with MRSA infections.40 An increased risk of failure was observed in

136

the high MIC group compared to the low MIC group (relative risk [RR], 1.40; 95% confidence

137

interval [CI], 1.15 – 1.71).

138

CI,1.08-1.87) in the high MIC group. Although the investigators attempted to exclude hVISA

139

isolates, hVISA presence was not tested in every study, which may have contributed to

140

vancomycin treatment responses.

141

heterogeneity cannot be excluded. Another study evaluated 559 MRSA isolates and found an

142

increased incidence of hVISA when the vancomycin MIC shifted from 1 to 2 μg/mL.41 The

143

incidence of hVISA was nearly 40% in isolates with an MIC of 2 μg/mL, supporting the results of

144

other studies that suggest the proportion of hVISA isolates are directly related to increases in

145

vancomycin MIC.6,15,23,41 Increases in vancomycin MICs are hospital specific and perhaps caused

146

by clonal outbreaks. However, this highlights the trends of vancomycin tolerance, which may be

Several studies have noted an increase in

A recent meta-analysis of 20 studies

There was also a greater risk of overall mortality (RR, 1.45; 95%

While most of the isolates were from blood, clinical

9
147

caused by overuse of vancomycin, sub-therapeutic vancomycin concentrations, high bacterial load,

148

or slow vancomycin bactericidal activity.3,42

149
150

Both hVISA and VISA have been identified in hospital and community strains of MRSA and in

151

MSSA.16 The findings of studies that evaluated clinical predictors and outcomes of hVISA

152

infections are inconsistent. This may be attributed to the considerable heterogeneity of these

153

studies, including differences in study design, clinical definitions, selection of isolates (initial

154

isolate, final isolate, or random selection), patient populations, and testing methodologies.

155

Commonly reported associations with hVISA infections include vancomycin treatment failure and

156

high-inoculum MRSA infections (e.g., bacteremia, infective endocarditis, osteomyelitis, deep

157

abscesses, and prosthetic device infections).6,7,14,33,43,44 Other potential predictors of hVISA and

158

VISA infections are prior MRSA infection or colonization (previous 3 months), previous

159

vancomycin exposure (prior 6 months), initial low serum vancomycin trough levels (< 10 µg/mL),

160

persistent bacteremia (≥ 7 days), and presence of indwelling devices (Table 2).7,8,12,14,44,45 46

161
162

Patients with hVISA infections tend to experience prolonged clinical courses, suboptimal response

163

to vancomycin therapy, and prolonged hospital stays.6-8,14,33,42,44 One retrospective case-control

164

study compared the clinical features and outcomes of hVISA bacteremia (n = 27) and MRSA

165

bacteremia (n = 223).14 Compared with MRSA bacteremia, patients with hVISA infections had

166

significantly more days of bacteremia (median duration, 12 days vs. 2 days, respectively; P =

167

0.005) and significantly higher rates of endocarditis (18.5% vs. 3.6%, respectively; P = 0.007) and

168

osteomyelitis (25.9% vs. 7.2%, respectively; P = 0.006).14 Of note, patients in the hVISA group

169

had significantly more prosthetic/implant devices (e.g., artificial heart valves, pacemakers, or

10
170

orthopedic implants) and surgical site infections (in the previous month) at baseline, which may

171

have attributed to poorer outcomes. In a small case series, glycopeptide treatment failure, (defined

172

as a positive S. aureus blood culture after  7 days of glycopeptide therapy or a sterile site culture

173

positive for S. aureus after  21 days of glycopeptide therapy) occurred in 19 of 25 (76%) patients

174

with hVISA infections (bacteremia, endocarditis, osteomyelitis, or septic arthritis).8

175
176

A retrospective, multicenter, matched cohort study compared the outcomes of hVISA versus

177

vancomycin susceptible-MRSA (VS-MRSA) bloodstream infections (BSI) and found similar

178

results.6 Study investigators concluded that rates of vancomycin treatment failure were 11 times

179

higher for a patient with hVISA BSI (50/61, 82%) than VS-MRSA BSI (20/61, 32.8%; P <0.001).

180

Patients with hVISA BSI were also more likely than patients with VS-MRSA BSI to have

181

persistent bacteremia (59% vs. 21.3%, respectively; P <0.001), infection recurrence at 60 days

182

(25.5% vs. 1.9%, respectively; P < 0.001), and longer hospital length of stay (median in days, 24

183

vs. 16, respectively; P = 0.022). While differences in 30-day MRSA infection-related mortality

184

and all-cause 30-day mortality were not observed between the hVISA BSI group and VS-MRSA

185

BSI group (21.3% vs. 9.8%; P = 0.081 and 24.6% vs. 11.5%; P = 0.076, respectively). Similarly,

186

no other studies have been powered to detect a significant difference in mortality between hVISA

187

and non-hVISA infections. A recent systematic review and meta-analysis evaluated 30-day

188

mortality from eight comparative hVISA studies.18 After combining the data, 30-day mortality

189

between hVISA and VSSA infections were similar (OR, 1.18; 95% CI, 0.81-1.74).18 However,

190

these findings may be limited by the variability in definitions used and the predominately

191

retrospective designs of the original studies. While the lack of association between hVISA and

192

mortality can be partly explained by strain characteristics (e.g., decreased virulence) and host

11
193

immune responses, sufficiently sized studies are needed to accurately determine if such an

194

association exits.47

195
196

Infections caused by VISA may also lead to recurrent infections, prolonged fevers and bacteremia,

197

vancomycin treatment failure, and increased hospital stay.7,12,33,44 In a single–center, retrospective

198

study, 6 patients with VISA had a significantly longer duration of bacteremia compared to 22 with

199

hVISA (12.1 ± 13.1 days vs. 3.3 ± 3.9 days, respectively; P = 0.001).43 Significant differences in

200

mortality between VISA and hVISA were not observed. However, rates of attributable mortality

201

between hVISA and VSSA (n = 215) were similar (9.1% vs. 8.4%, respectively) while those

202

between VISA and VSSA (33.3% vs. 8.4%) were not.43

203

limitations including a small sample size and bias through selective inclusion of isolates, the

204

findings suggest that VISA may have more severe clinical implications and impact on patient

205

outcomes. To date, no other published study has evaluated the outcomes of VISA infections,

206

possibly because of the rarity of VISA infections.

Although this study had several

207
208

Treatment Options for hVISA/VISA Infections

209

Although reports of vancomycin failure have emerged, no data demonstrate superior outcomes

210

with alternative antimicrobials.

211

hVISA/VISA include daptomycin, linezolid, ceftaroline, trimethoprim/sulfamethoxazole,

Alternative antimicrobial agents with activity against

12
212

tigecycline, quinupristin/dalfopristin, and the combination of vancomycin or daptomycin with a

213

beta-lactam.12

214
215

Daptomycin

216

Daptomycin is a potential treatment option for hVISA and VISA infections and, although it does

217

have activity against MRSA, previous vancomycin exposure can result in some degree of cross-

218

resistance to daptomycin.48,49

219

increasing vancomycin MICs and increasing daptomycin non-susceptibility.48-50 The highest rate

220

of daptomycin non-susceptibility was reported in a study evaluating 47 Australian hVISA and

221

VISA isolates never exposed to daptomycin.50 The investigators noted daptomycin non-

222

susceptibly in 15% of hVISA and 38% of VISA strains.50 Because bactericidal activity with

223

daptomycin is concentration dependent, higher doses may be necessary to treat hVISA and VISA

224

infections with elevated daptomycin MICs, high inoculum infections (e.g., endocarditis), and

225

infection sites characterized by poor antimicrobial penetration.51 High-dose daptomycin may

226

prevent the selection or development of isolates with reduced susceptibility to daptomycin and

227

subsequent treatment failure.51

Several studies have noted an in vitro association between

228
229

An in vitro study observed more rapid reduction of bacterial burden of hVISA and VISA in

230

simulated endocardial vegetations with high-dose daptomycin (10 mg/kg/day for 8 days) and dose

231

de-escalation (10 mg/kg/day for 4 days followed by 6 mg/kg/day for 4 days) regimens compared

232

to that of the standard (6 mg/kg/day for 8 days) and dose escalation (6 mg/kg/day for 4 days

233

followed by 10 mg/kg/day for 4 days) regimens.51 With respect to hVISA, the dose de-escalation

234

regimen had a significantly increased killing effect on the hVISA strain compared to the dose

13
235

escalation regimen (P < 0.024).51 The investigators concluded that these daptomycin dosing

236

approaches may lead to a faster cure of bacteremia in vivo and prevent the emergence of

237

daptomycin non-susceptibility.51 However, no in vivo studies evaluating de-escalation dosing and

238

the appropriate duration of high-dose daptomycin have been published. The role of high-dose

239

daptomycin alone in patients with hVISA or VISA infections is unclear. Until more evidence is

240

available, caution is required when considering daptomycin in patients who may be at risk for

241

hVISA or VISA infections (e.g. high-bacterial load infections, vancomycin failure).

242

determination of daptomycin susceptibility in these patients may also guide therapeutic decision

243

making.

The

244
245

Linezolid

246

The role of linezolid for the treatment of invasive hVISA and VISA infections is also in question.

247

Successful use of linezolid alone or in combination with other antimicrobial agents has been

248

described in several case reports of vancomycin heteroresistant and intermediate MRSA

249

endocarditis and bacteremias after vancomycin failure and in some cases after daptomycin

250

failure.8,52-55 In one case report, a 60 year old male with an automatic implantable cardioverter-

251

defibrillator (AICD) presented with bacteremia and endocarditis initially caused by MRSA which

252

later developed into hVISA, then daptomycin non-susceptible VISA after exposure to vancomycin

253

and daptomycin.55 The patient initially received 6 weeks of vancomycin (trough concentrations

254

between ≥ 15 µg/mL and ≤ 21 µg/mL), followed by approximately 25 days of daptomycin (6

255

mg/kg every 48 hours, renal dose adjusted). During therapy with daptomycin the defibrillator

256

generator and leads were removed however, the patient was persistently bacteremic and febrile.

257

Blood cultures cleared after therapy was switched to linezolid and trimethoprim/sulfamethoxazole.

14
258

The patient received at least 28 days of the combination and 6 weeks of linezolid monotherapy in

259

total since the last positive blood culture. One year post-treatment the patient had no infection

260

recurrence. After failing vancomycin and daptomycin therapy, this patient’s VISA infection was

261

successfully treated with linezolid. While other case reports have shown similar outcomes with

262

the use of linezolid, in vitro studies have not shown the same efficacy.56 Evidence to recommend

263

the use of linezolid for hVISA and VISA is insufficient. Further study is needed to evaluate

264

linezolid alone or in combination for hVISA and VISA infections.

265
266

Ceftaroline

267

Ceftaroline has potent in vitro bactericidal activity against MRSA including hVISA, VISA, and

268

daptomycin non-susceptible (DNS) MRSA strains.57 The use of ceftaroline in the treatment of

269

invasive infections (e.g., endocarditis, bacteremia, osteomyelitis) caused by hVISA, VISA, and

270

DNS MRSA is supported by data from in vivo animal studies and human case reports.58-61 In a

271

recent case series report, a patient with DNS VISA bacteremia and endocarditis was successfully

272

treated with 6 weeks of ceftaroline. The patient initially received and failed vancomycin therapy.62

273

Blood cultures cleared within 48 hours of switching to daptomycin (6 mg/kg/day). However,

274

subsequent blood cultures were positive and revealed DNS VISA. Daptomycin was discontinued,

275

and ceftaroline (600 mg IV every 8 hours) was initiated. While on ceftaroline, blood cultures

276

cleared within 48 hours and remained sterile. In vitro pharmacokinetic/pharmacodynamic studies

277

reported enhanced ceftaroline activity against hVISA, VISA, and DNS MRSA as vancomycin and

278

daptomycin susceptibilities decreased, which have been referred to as the “seesaw effect”.58-60

279

While further study is needed, ceftaroline appears to be a safe and effective alternative in the

15
280

treatment of invasive hVISA, VISA, and DNS MRSA infections given its bactericidal activity,

281

favorable safety profile, and emerging data.

282
283

Combination therapy

284

The combination of vancomycin or daptomycin and a beta-lactam antimicrobial has also been

285

studied for treatment of hVISA and VISA infections. Beta-lactams that have been evaluated for

286

synergistic activity with vancomycin or daptomycin include ceftaroline, cefazolin, and

287

piperacillin-tazobactam.63-66 In vitro and clinical case report data evaluating the combination of

288

high-dose daptomycin (10 mg/kg/day) and trimethoprim/sulfamethoxazole also appear promising

289

for the treatment of hVISA, VISA, and DNS MRSA infections.67,68 In vitro studies have

290

demonstrated improved kill rates with these antimicrobial combinations.63-65

291

hypothesize that beta-lactam exposure may influence vancomycin-cell wall interactions to

292

improve vancomycin activity, although further investigation is warranted.63

293

preliminary experimental studies show possible prospects for the treatment of hVISA and VISA

294

infections. However, it is not yet clear which treatment options correlate with optimal clinical

295

outcomes for patients with confirmed hVISA or VISA infections.

Investigators

In summary,

296
297

Infection Control: Preventing the Dissemination of hVISA/VISA

298

As with MRSA, hVISA and VISA can colonize humans and the environment despite eradication

299

efforts. The CDC has made several recommendations in an attempt to prevent the emergence of

300

vancomycin non-susceptible infections.42 Infections with confirmed VISA should be reported to

301

infection-control personnel, the patient’s primary caregiver, medical ward staff, local and state

302

departments of health, and the CDC. Patients and their caregivers should be educated regarding

16
303

wound care, physical hygiene, and signs of infection.69 Contact isolation in both the inpatient and

304

outpatient setting may also limit further emergence.

305

prevention and control guidelines, appropriate antibiotic prescribing through antimicrobial

306

stewardship programs, and active surveillance in a cohesive health care system are essential to

307

prevent further emergence of hVISA and VISA colonization and infection.

Adherence to recommended infection

308
309

Conclusions

310

The evolution of S. aureus to MRSA and now to hVISA and VISA is an important and ongoing

311

public health concern. Vancomycin is the drug of choice for invasive MRSA infections, however,

312

its use is under question. Over-use, suboptimal concentrations, or inappropriate use of vancomycin

313

is speculated to be a major contributor in the emergence of hVISA and VISA. Most alarming are

314

the poor outcomes that have been associated with hVISA and VISA infections and the limited

315

antimicrobials available to treat these infections. Proper detection methods are necessary for

316

accurate surveillance, guidance on therapeutic decision-making, and a full understanding of the

317

implications of hVISA/VISA infections. Until then, patients who are at risk for hVISA/VISA

318

infections and failing vancomycin therapy may warrant further confirmatory testing for

319

hVISA/VISA. Based on currently available data, clinicians should, with vigilance, continue to use

320

vancomycin per the Infectious Diseases Society of America guidelines.2,3 Alternative therapies

321

should be considered in patients with risk factors for hVISA/VISA who are not responding

322

clinically to vancomycin despite source control and a vancomycin MIC ≤ 2 µg/mL. In patients

323

infected with VISA (vancomycin MIC 4 – 8 µg/mL), an alternative antimicrobial should be

324

considered. Caution is advised when deciding to use daptomycin in patients with hVISA/VISA

17
325

infections because of the potential for cross-resistance. To prevent further resistance, appropriate

326

use of antimicrobials and implementation of infection-control guidelines are imperative.
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Table 1. CLSI susceptibility definitions for vancomycin24,25
2006 CLSI Update
Previous CLSI Breakpoints
MIC
MIC
a
VSSA
≤ 2 g/mL
 4 g/mL
VISA
4 – 8 g/mL
8 – 16 g/mL
VRSA
≥ 16 g/mL
 32 g/mL
CLSI = Clinical and Laboratory Standards Institute; MIC = minimum inhibitory concentration;
VISA = vancomycin intermediate S. aureus; VRSA = vancomycin resistant S. aureus; VSSA = vancomycin susceptible S. aureus;
a
May contain heteroresistant intermediate susceptible subpopulations with MIC > 4 g/mL. Heteroresistant vancomycin intermediate S. aureus
(hVISA) isolates are not identified by CLSI and can occur at vancomycin MICs as low as 0.5 µg/mL.

27

Table 2. Advantages and disadvantages of laboratory detection methods for hVISA
Confirmatory Methods
Method
PAP4,11,13,26,70

Advantages
 Considered the “gold
standard”
 High reproducibility and
accurate detection
 Definitive confirmation:
Modified PAP

Disadvantages
 No data to show superiority to
other techniques
 High labor intensity
 High-cost
 Long turn-around time

Screening Methods
Method
GRD E-test
(AB Biodisk)17,19,27

Advantages

Disadvantages

 Results ready to read following
24 hours of incubation
 Uses standard bacterial
inoculum

 Unreliable specificity and
sensitivity

MET or
High inoculum
method11,29

 100% reproducibility
 Easily performed

 Testing performed on
nonstandard media while
utilizing a standard McFarland
suspension
 Results of MET are cut-off
points, not true MICs

BHI screen agar
plates7,17,28

 Easily performed

 Poor reproducibility
 Many variations; some studies
screened with a different agar,
inoculum size, or used
suspensions with higher
bacterial concentration

BHI = Brain Heart Infusion; GRD = Glycopeptide Resistance Detection; MET = Macromethod E-Test; MIC = minimum inhibitory concentration;
PAP = Population Analysis Profiling

28
Table 3. Predictors and outcomes of hVISA and VISA
Predictors
Outcomes
 Previous vancomycin use
 Long duration of bacteremia, days
 Prior MRSA infection or colonization
 Persistent fever
a
 High bacterial load infections
 Recurrent infections
 Persistent bacteremia
 Vancomycin treatment failure
 Initally low serum vancomycin levels
 Prolonged hospitalization
(<10 μg /mL)
 Presence of indwelling devices
hVISA = heteroresistant vancomycin intermediate S. aureus; MRSA = methicillin resistant S. aureus; VISA = vancomycin intermediate S. aureus
a

E.g.bacteremia, endocarditis, osteomyelitis, deep abscess, or prosthetic joint infection

